Rhenman & Partners Asset Management Ab Agios Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$44.23 - $57.5 $5.75 Million - $7.48 Million	-130,000 Closed	0 $0
Q4 2020 Jan 19, 2021	BUY	$33.21 - $46.54 $1.33 Million - $1.86 Million	40,000 Added 44.44%	130,000 $5.63 Million
Q2 2020 Jul 16, 2020	SELL	$34.45 - $53.48 $689,000 - $1.07 Million	-20,000 Reduced 18.18%	90,000 $4.81 Million
Q1 2020 Apr 16, 2020	SELL	$31.52 - $53.81 $1.58 Million - $2.69 Million	-50,000 Reduced 31.25%	110,000 $3.9 Million
Q4 2019 Jan 17, 2020	SELL	$30.08 - $50.59 $2.56 Million - $4.3 Million	-85,002 Reduced 34.69%	160,000 $7.64 Million
Q3 2019 Oct 16, 2019	BUY	$32.4 - $49.58 $1.46 Million - $2.23 Million	45,002 Added 22.5%	245,002 $7.94 Million
Q2 2019 Jul 22, 2019	BUY	$46.17 - $68.1 $3.37 Million - $4.97 Million	72,988 Added 57.47%	200,000 $9.98 Million
Q4 2018 Feb 05, 2019	SELL	$42.73 - $76.53 $786,915 - $1.41 Million	-18,416 Reduced 12.66%	127,012 $5.86 Million
Q3 2018 Oct 03, 2018	SELL	$71.67 - $91.95 $1.08 Million - $1.38 Million	-15,000 Reduced 9.35%	145,428 $11.2 Million
Q2 2018 Jul 20, 2018	BUY	$73.22 - $99.55 $4.79 Million - $6.51 Million	65,428 Added 68.87%	160,428 $13.5 Million
Q1 2018 Apr 11, 2018	SELL	$59.83 - $86.53 $299,150 - $432,650	-5,000 Reduced 5.0%	95,000 $7.77 Million
Q4 2017 Jan 19, 2018	BUY	$52.12 - $72.33 $4.43 Million - $6.15 Million	85,000 Added 566.67%	100,000 $5.72 Million
Q3 2017 Oct 13, 2017	BUY	$54.89 - $67.12 $823,350 - $1.01 Million	15,000	15,000 $1 Million

226

56.3M

275K

251K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $2.44B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.